Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TEVA
stocks logo

TEVA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
4.40B
+3.94%
0.661
-6.84%
4.01B
+3.07%
0.583
+12.18%
4.21B
+0.86%
0.660
0%
Estimates Revision
The market is revising Upward the revenue expectations for Teva Pharmaceutical Industries Limited (TEVA) for FY2025, with the revenue forecasts being adjusted by 0.44% over the past three months. During the same period, the stock price has changed by 53.73%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.44%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+2.7%
In Past 3 Month
Stock Price
Go Up
up Image
+53.73%
In Past 3 Month
Wall Street analysts forecast TEVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEVA is 29.25 USD with a low forecast of 28.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast TEVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEVA is 29.25 USD with a low forecast of 28.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 28.410
sliders
Low
28.00
Averages
29.25
High
32.00
Current: 28.410
sliders
Low
28.00
Averages
29.25
High
32.00
JPMorgan
Chris Schott
Overweight
maintain
$26 -> $28
2025-11-06
Reason
JPMorgan
Chris Schott
Price Target
$26 -> $28
2025-11-06
maintain
Overweight
Reason
JPMorgan analyst Chris Schott raised the firm's price target on Teva to $28 from $26 and keeps an Overweight rating on the shares. The company reported solid Q3 results, the analyst tells investors in a research note.
Goldman Sachs
Matt Dellatorre
Buy
maintain
$25 -> $28
2025-11-06
Reason
Goldman Sachs
Matt Dellatorre
Price Target
$25 -> $28
2025-11-06
maintain
Buy
Reason
Goldman Sachs analyst Matt Dellatorre raised the firm's price target on Teva to $28 from $25 and keeps a Buy rating on the shares.
UBS
Buy
maintain
$23 -> $26
2025-09-24
Reason
UBS
Price Target
$23 -> $26
2025-09-24
maintain
Buy
Reason
UBS raised the firm's price target on Teva to $26 from $23 and keeps a Buy rating on the shares. The stock can continue to see a relief rally as the Austedo IRA price gets revealed by November 30 or earlier, the analyst tells investors in a research note. Payor insights suggest that the potential IRA discount on Austedo could be about 40% off the list price, UBS says.
Piper Sandler
Overweight
downgrade
$30 -> $29
2025-07-29
Reason
Piper Sandler
Price Target
$30 -> $29
2025-07-29
downgrade
Overweight
Reason
Piper Sandler lowered the firm's price target on Teva to $29 from $30 and keeps an Overweight rating on the shares ahead of quarterly results. The firm says performance for biopharma in Q2 and into Q3 thus far has seen marked improvement, in part a function of fears surrounding tariff-related dislocation receding into the background, in part a function of fears regarding pricing-related dislocation also receding into the background, and in part a function of an anticipated more favorable rate environment. With that said, Piper believes that choppy waters, or perceptions thereof, will continue to render profitable bigger caps as something of a safer haven.
UBS
Buy
maintain
$24 -> $23
2025-06-26
Reason
UBS
Price Target
$24 -> $23
2025-06-26
maintain
Buy
Reason
UBS lowered the firm's price target on Teva to $23 from $24 and keeps a Buy rating on the shares. Despite steady execution progress on its mid- and long-term outlook, shares are down 20% year-to-date, and UBS thinks the stock has been penalized more unfairly than most of the rest of biopharma. Teva management has addressed multiple investor concerns by stabilizing U.S. generics, rekindling Austedo growth from a sleeper, proved R&D execution, and solving the Revlimid cliff, the analyst tells investors in a research note.
Evercore ISI
Outperform
initiated
2025-06-21
Reason
Evercore ISI
Price Target
2025-06-21
initiated
Outperform
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Teva Pharmaceutical Industries Ltd (TEVA.N) is 0.00, compared to its 5-year average forward P/E of 4.66. For a more detailed relative valuation and DCF analysis to assess Teva Pharmaceutical Industries Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
4.66
Current PE
0.00
Overvalued PE
6.37
Undervalued PE
2.95

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
6.93
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
7.48
Undervalued EV/EBITDA
6.37

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.86
Current PS
0.00
Overvalued PS
1.14
Undervalued PS
0.58
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

TEVA News & Events

Events Timeline

(ET)
2025-12-03
10:10:00
Evercore ISI Sees Cash Flow 'Way Over' $3B in 2030
select
2025-11-25 (ET)
2025-11-25
08:12:35
Teva Secures EC Approvals for PONLIMSI and DEGEVMA
select
2025-11-07 (ET)
2025-11-07
18:03:35
Teva Pharma: Austedo and Austedo XR Show Beneficial Real-World Effects
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.0
12-04SeekingAlpha
Mark Cuban advocates for eliminating fees on generic drug applications to enhance domestic production.

  • Mark Cuban's Proposal: Mark Cuban is advocating for the Trump administration to eliminate the $360K regulatory fee for generic drug applications to boost domestic production of high-cost generic medications.

  • Cost Plus Drugs' Capability: Cuban stated that if the fees are waived, Cost Plus Drugs could begin manufacturing expensive generic drugs, such as those for rare diseases, within a year from their Dallas facility.

[object Object]
Preview
4.5
12-02NASDAQ.COM
Significant ETF Inflows: IEFA, SPOT, SE, TEVA

  • 52-Week Range Analysis: IEFA's share price has a 52-week low of $66.95 and a high of $89.98, with the last trade recorded at $88.44.

  • Understanding ETFs: Exchange traded funds (ETFs) function like stocks, where investors buy and sell "units" that can be created or destroyed based on demand.

  • Monitoring ETF Flows: Weekly monitoring of shares outstanding helps identify ETFs with significant inflows (new units created) or outflows (units destroyed), impacting the underlying holdings.

  • Disclaimer: The views expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.

[object Object]
Preview
9.0
11-25NASDAQ.COM
Teva Receives Marketing Approvals from European Commission for Biosimilars PONLIMSI and DEGEVMA

  • Teva Pharmaceuticals Announcement: Teva Pharmaceuticals International has received marketing authorizations from the European Commission for two denosumab biosimilar candidates, PONLIMSI and DEGEVMA.

  • Product Launch Plans: Teva plans to launch these biosimilars, which are alternatives to Prolia and Xgeva, in key European markets in the coming months.

  • Impact on Patient Access: Steffen Nock, SVP Head of Biosimilars & Chief Science Officer, emphasized that this approval is a significant advancement in improving patient access to biosimilar therapies for serious bone conditions.

  • Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Teva Pharmaceutical Industries Ltd (TEVA) stock price today?

The current price of TEVA is 28.41 USD — it has increased 2.08 % in the last trading day.

arrow icon

What is Teva Pharmaceutical Industries Ltd (TEVA)'s business?

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

arrow icon

What is the price predicton of TEVA Stock?

Wall Street analysts forecast TEVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEVA is 29.25 USD with a low forecast of 28.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Teva Pharmaceutical Industries Ltd (TEVA)'s revenue for the last quarter?

Teva Pharmaceutical Industries Ltd revenue for the last quarter amounts to 4.48B USD, increased 3.42 % YoY.

arrow icon

What is Teva Pharmaceutical Industries Ltd (TEVA)'s earnings per share (EPS) for the last quarter?

Teva Pharmaceutical Industries Ltd. EPS for the last quarter amounts to 0.37 USD, decreased -194.87 % YoY.

arrow icon

What changes have occurred in the market's expectations for Teva Pharmaceutical Industries Ltd (TEVA)'s fundamentals?

The market is revising Upward the revenue expectations for Teva Pharmaceutical Industries Limited (TEVA) for FY2025, with the revenue forecasts being adjusted by 0.44% over the past three months. During the same period, the stock price has changed by 53.73%.
arrow icon

How many employees does Teva Pharmaceutical Industries Ltd (TEVA). have?

Teva Pharmaceutical Industries Ltd (TEVA) has 33892 emplpoyees as of December 05 2025.

arrow icon

What is Teva Pharmaceutical Industries Ltd (TEVA) market cap?

Today TEVA has the market capitalization of 32.59B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free